摘要
目的比较顺铂联合紫杉醇与顺铂联合美洛昔康对卵巢癌患者血清血管内皮生长因子(VEGF)、基质金属蛋白酶2(MMP-2)水平影响及近远期疗效。方法前瞻性研究选择2014年6月至2015年2月收治的卵巢癌患者88例为研究对象,采用随机数字表法分为研究组(44例)及对照组(44例)。对照组患者给予紫杉醇+顺铂治疗,观察组患者给予顺铂+口服美洛昔康片治疗,均以3周为1个疗程。比较两组患者的治疗疗效,治疗前、治疗后1周、4周、8周血清VEGF、MMP-2及前列腺素E2(PGE-2)动态变化,中位至疾病进展时间(TTP),治疗后3年内总生存期及不良反应发生情况。结果观察组治疗后的总有效率显著高于对照组(P<0.05);治疗后观察组患者各时段血清VEGF、MMP-2、PGE-2水平均显著低于对照组,差异具有统计学意义(P<0.05);观察组及对照组的中位TTP分别为(11.23±2.73)个月、(8.91±2.69)个月,观察组的中位TTP高于对照组,差异具有统计学意义(P<0.05);观察组1、2、3年总生存率(95.47%、63.68%、25.00%)略高于对照组(93.18%、61.36%、22.73%),但差异无统计学意义(P>0.05);观察组皮疹、口腔溃疡、色素沉着发生率明显低于对照组,差异具有统计学意义(P<0.05)。结论美昔洛康+顺铂方案治疗晚期卵巢癌疗效优于紫杉醇+顺铂方案,降低肿瘤组织转移性指标,同时延长患者中位TTP,安全性高。
Objective To discuss the influence of Cisplatin combined with paclitaxel and meloxicam on the level of VEGF and MMP-2 in serum of patients with ovarian cancer and the short and long term curative effect comparison. Methods 88 patients with ovarian cancer treated in our hospital from June 2014 to February 2015 were randomly divided into study group（ 44 cases） and control group（ 44 cases）. The control group patients were given cisplatin combined with paclitaxel,the study group patients were given cisplatin combined with paclitaxel and meloxicam treatment. The two groups were 3 weeks for 1 courses of treatment,compared the therapeutic effects of the two groups. The dynamic changes of serum vascular endothelial growth factor（ VEGF）,matrix metallo-proteinase-2（ MMP-2） and prostaglandin E2（ PGE-2） before and after treatment,the median time to progression（ TTP）,the overall survival and adverse events within 3 years after treatment. Results After treatment,the total effective rate of the observation group was significantly higher than that of the control group（ P〈0. 05）. The levels of serum VEGF,MMP-2 and PGE-2 in the observation group were significantly lower than those in the control group,and the difference was statistically significant（ P〈0. 05）. The median TTP of observation group and control group respectively（ 11. 23 ± 2. 73） months,（ 8. 91 ± 2. 69） months,the difference between the groups was significant（ P〈0. 05）. The overall 1,2,3 years survival rates of the observation group and the control group were95. 47 %,63. 68 %,25. 00 % and 93. 18 %,61. 36 %,22. 73 %,respectively,and there was no significant difference between the two groups（ P〈0. 05）. The incidence of skin rashes,oral ulcers and pigmentation in the observation group were significantly lower than those of the control group（ P〈0. 05）. Conclusion The meloxicam and cisplatin in the treatment of advanced ovarian cancer is better than paclitaxel ＋ cisplatin,reduce the metastasis index of tumor
作者
袁绍曲
刘丛海
戚瑞红
YUAN Shao - qu;LIU Cong - hai;QI Rui - hong(Department of Outpa- tient Pharmacy;Department of Obstetrics and Gynecology, Dazhou Central Hospital, Dazhou Sichuan 635000, China.)
出处
《临床和实验医学杂志》
2018年第9期952-955,共4页
Journal of Clinical and Experimental Medicine
关键词
卵巢癌
顺铂
紫杉醇
美洛昔康
安全性
Ovarian cancer
Cisplatin
Taxol
Meloxicam
Vascular endothelial growth factor
Matrix metalloproteinase - 2
